Genzyme

brand-profile-thumb

Company Headquarters

50 Binney St Cambridge, Massachusetts 02142 US

Driving Directions

Brand Description

Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, rare blood disorders, neurology, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.

Key Personnel

NAME
JOB TITLE
  • Paul Hudson
    Chief Executive Officer
  • Houman Ashrafian
    Executive Vice President, Head of Research and Development
  • Natalie Bickford
    Executive Vice President, Chief People Officer
  • Olivier Charmeil
    Executive Vice President, General Medicines
  • Audrey Duval Derveloy
    Executive Vice President, Corporate Affairs
  • Brian Foard
    Executive Vice President, Head of Specialty Care
  • Emmanuel Frenehard
    Executive Vice President, Chief Digital Officer
  • Brendan O
    Executive Vice President, Manufacturing and Supply
  • Roy Papatheodorou
    Executive Vice President, General Counsel
  • Madeleine Roach
    Executive Vice President, Business Operations
  • Fran
    Executive Vice President, Chief Financial Officer
  • Thomas Triomphe
    Executive Vice President, Vaccines
  • Julie Van Ongevalle
    Executive Vice President, Consumer Healthcare

Yearly results

Sales: 3.4 Million

Sales: 3.4 Million

Headcount: 10,100
Pharma Revenues: $3,417 (1%)
Total Revenues: $4,085 (3%)
Net Income: $32 (-93%)
R&D Budget: $847 (2%)

Top-Selling Drugs in 2010

Drug

Indication

$

(+/- %)

Cerezyme

Gaucher disease

$720

-9%

Renagel

hemodialysis

$698

-1%

Fabrazyme

Fabry disease

$188

-56%

Myozyme

Pompe disease

$412

27%

Thymoglobulin/Lymphoglobulin

transplantation $230 6%

Aldurazyme

mucopolysaccharidosis

$167

8%

Thyrogen

thyroid cancer

$182

7%

Hectorol

renal disease

$190

46%

Account for 82% of total biopharma sales, down from 86% in 2009.

Previous Profile: CSL // Next Profile: Allergan

Related Content